TY - JOUR
T1 - Effect of medication adherence on disease activity among Japanese patients with rheumatoid arthritis
AU - Nakagawa, Shunsaku
AU - Nakaishi, Mayumi
AU - Hashimoto, Motomu
AU - Ito, Hiromu
AU - Yamamoto, Wataru
AU - Nakashima, Ran
AU - Tanaka, Masao
AU - Fujii, Takao
AU - Omura, Tomohiro
AU - Imai, Satoshi
AU - Nakagawa, Takayuki
AU - Yonezawa, Atsushi
AU - Imai, Hirohisa
AU - Mimori, Tsuneyo
AU - Matsubara, Kazuo
N1 - Funding Information:
The authors have read the journal's policy and the authors of this manuscript have the following competing interests: M. Hashimoto and M. Tanaka are affiliated with the department that is financially supported by four pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd, UCB Japan Co. Ltd, and AYUMI Pharmaceutical Co.). M. Hashimoto has received research grants from Astellas and Bristol-Myers. H. Ito has received a research grant and/or speaker fee from Bristol-Myers, Astellas and Asahi-Kasei. KURAMA cohort study is supported by grant from Daiichi Sankyo Co. Ltd. This study is conducted as investigator initiate study. These companies had no role in the design of the study, the collection or analysis of the data, the writing of the manuscript or decision to submit the manuscript for the publication. T. Fujii has received a research grant and/or speaker fee from Pfizer Japan Inc., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Co.,Ltd., Mitsubishi-Tanabe Pharma Corporation, Eisai Co.,Ltd., AbbVie GK, and Astellas Pharma Inc. S. Nakagawa, M. Nakaishi, W. Yamamoto, R. Nakashima, T. Omura, S. Imai, T. Nakagawa, A. Yonezawa, H. Imai, T. Mimori and K. Matsubara have declared that no competing interests exist. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Publisher Copyright:
© 2018 Nakagawa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2018/11
Y1 - 2018/11
N2 - For the optimum efficacy of disease-modifying anti-rheumatic drugs (DMARDs), patients need to be adherent to their medication regimen. To clarify the effects of medication adherence on disease activity in Japanese patients with rheumatoid arthritis (RA), we conducted a cohort study in patients with various stages of RA. Patients were enrolled from the Kyoto University RA Management Alliance cohort, and followed up prospectively for 12 months. In this study, a total of 475 patients were analyzed and divided into 9 groups according to their medication adherence and the RA disease duration. The primary outcomes were based on the rate of a disease flare. The secondary outcomes were the changes in disease activity score using 28 joints (DAS28-ESR), simplified disease activity index (SDAI) and physical disability by health assessment questionnaire-disability index (HAQ). The changes in DAS28-ESR, HAQ, and the risk of disease flare in the highly adherent patients were significantly lower than those of the less adherent patients among the groups with RA 4.6 years but not those among the other groups. Taken together, this study identified a significant association between medication adherence and the disease flare during early-stage RA or short disease duration. These results emphasize the need to pay more attention to medication adherence in preventing the disease progression of RA.
AB - For the optimum efficacy of disease-modifying anti-rheumatic drugs (DMARDs), patients need to be adherent to their medication regimen. To clarify the effects of medication adherence on disease activity in Japanese patients with rheumatoid arthritis (RA), we conducted a cohort study in patients with various stages of RA. Patients were enrolled from the Kyoto University RA Management Alliance cohort, and followed up prospectively for 12 months. In this study, a total of 475 patients were analyzed and divided into 9 groups according to their medication adherence and the RA disease duration. The primary outcomes were based on the rate of a disease flare. The secondary outcomes were the changes in disease activity score using 28 joints (DAS28-ESR), simplified disease activity index (SDAI) and physical disability by health assessment questionnaire-disability index (HAQ). The changes in DAS28-ESR, HAQ, and the risk of disease flare in the highly adherent patients were significantly lower than those of the less adherent patients among the groups with RA 4.6 years but not those among the other groups. Taken together, this study identified a significant association between medication adherence and the disease flare during early-stage RA or short disease duration. These results emphasize the need to pay more attention to medication adherence in preventing the disease progression of RA.
UR - http://www.scopus.com/inward/record.url?scp=85056050943&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056050943&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0206943
DO - 10.1371/journal.pone.0206943
M3 - Article
C2 - 30388179
AN - SCOPUS:85056050943
SN - 1932-6203
VL - 13
JO - PloS one
JF - PloS one
IS - 11
M1 - e0206943
ER -